tbuckley/cabot-search huggingface dataset:
Response to Joshi et al’s “Considerations for perioperative antibiotic prophylaxis in Mohs micrographic surgery”
Authors: Kyle C. Lauck, Hamza Malick, Stanislav N. Tolkachjov
Journal: Journal of the American Academy of Dermatology (2023)

To the Editor: We appreciate the valuable commentary provided by Joshi et al regarding our recent work examining the utilization of perioperative empiric antibiotic therapy (PEAT) in Mohs micrographic surgery (MMS) and subsequent risk of surgical site infection (SSI).1,2 We agree with many of the comments they propose and believe it would be pertinent to provide more detail where space constraints may have limited detail in the original research letter. Our responses to their comments are outlined below.
Artificial Neural Processing‐Driven Bioelectronic Nose for the Diagnosis of Diabetes and Its Complications (Adv. Healthcare Mater. 26/2023)
Authors: Woong Bi Jang, Dongwon Yi, Thanh Mien Nguyen, Yujin Lee, Eun Ji Lee, Jaewoo Choi, You Hwan Kim, Eun‐Jung Choi, Jin‐Woo Oh, Sang‐Mo Kwon
Journal: Advanced Healthcare Materials (2023)
Visual Acuity Outcomes and Complications after Intraocular Lens Exchange
Authors: Hyeck-Soo Son, David F. Chang, Charles Li, Lynn Liu, Sidra Zafar, Flora Lum, Fasika A. Woreta
Journal: Ophthalmology (2023)

To assess risk factors for worse visual acuity (VA) outcomes after intraocular lens (IOL) exchange, and the most common postsurgical complications.
Four Ounces Can Move a Thousand Pounds: The Enormous Value of Nanomaterials in Tumor Immunotherapy (Adv. Healthcare Mater. 26/2023)
Authors: Ziyin Chen, Ziqi Yue, Kaiqi Yang, Congrong Shen, Zhe Cheng, Xiaofeng Zhou, Shenglong Li
Journal: Advanced Healthcare Materials (2023)

Nanomaterials for Immunotherapy The development and application of nanomaterials in tumor immunotherapy is promising. Nanomaterials used for tumor immunotherapy can be distinguished as organic and inorganic nanomaterials. Although both can achieve the purpose of tumor immunotherapy, the differences in their composition and structural properties lead to differences in their mechanisms and modes of action. Such various nanomaterials for immunotherapy are reviewed in article 2300882 by Xiaofeng Zhou, Shenglong Li, and co-workers.
Preclinical Development and Validation of Translational Temperature Sensitive Iodized Oil Emulsion Mediated Transcatheter Arterial Chemo‐Immuno‐Embolization for the Treatment of Hepatocellular Carcinoma (Adv. Healthcare Mater. 26/2023)
Authors: Heegon Kim, Bongseo Choi, Samdeep K. Mouli, Hyunjun Choi, Kathleen R. Harris, Laura M. Kulik, Robert J. Lewandowski, Dong‐Hyun Kim
Journal: Advanced Healthcare Materials (2023)

Interventional Oncology Immunotherapy In article 2300906 by Dong-Hyun Kim and co-workers, incorporation of CpG molecules into a lipiodol-based emulsion, and its transarterial delivery performing transcatheter arterial chemo-immuno-embolization (TACIE), successfully induces robust local/systemic anti-tumor immunity and regression of hepatocellular carcinoma (HCC). The TACIE approach combining TACE and local delivery of immune adjuvant suggests a new form of local interventional oncology immunotherapy for the treatment of HCC.
Moderate‐Affinity Affibodies Modulate the Delivery and Bioactivity of Bone Morphogenetic Protein‐2 (Adv. Healthcare Mater. 26/2023)
Authors: Jonathan Dorogin, Henry B. Hochstatter, Samantha O. Shepherd, Justin E. Svendsen, Morrhyssey A. Benz, Andrew C. Powers, Karly M. Fear, Jakob M. Townsend, James S. Prell, Parisa Hosseinzadeh, Marian H. Hettiaratchi
Journal: Advanced Healthcare Materials (2023)

Controlled Protein Delivery Article 2300793 by Marian H. Hettiaratchi and co-workers presents an innovative strategy for controlling the delivery of bone morphogenetic protein-2 (BMP-2) using affinity interactions with BMP-2-specific affibody proteins that are discovered using directed evolution. Two unique affibodies that are predicted to bind to different sites on BMP-2 are used to tune BMP-2 release from a hydrogel and modulate its osteogenic activity.
Copper Increases the Sensitivity of Cholangiocarcinoma Cells to Tripterine by Inhibiting TMX2‐Mediated Unfolded Protein Reaction Activation (Adv. Healthcare Mater. 26/2023)
Authors: Hongwen Liu, Lei Xu, Yiyang Zhang, Yiqiong Xie, Lishan Wang, Yue Zhou, Zhangding Wang, Yani Pan, Wenying Li, Lu Xu, Xinyun Xu, Ting Wang, Kui Meng, Jian He, Yudong Qiu, Guifang Xu, Weihong Ge, Yun Zhu, Lei Wang
Journal: Advanced Healthcare Materials (2023)

Chemotherapy Resistance Chemotherapy resistance is a big problem in treating cancer. In article 2300913, Yun Zhu, Lei Wang, and co-workers develop CuET-Lipid@Cela, in which copper inhibits Cela-induced UPR activation by reducing the translation efficiency of GRP78/BiP and find that the TMX2 gene may play an important role. Combination therapy is effective in a mouse model of CCA. The results highlight the potential of CuET targeting the TMX2/GRP78/BiP axis to overcome chemotherapeutic resistance in CCA.
Sublingual Dissolving Microneedle (SLDMN)‐Based Vaccine for Inducing Mucosal Immunity against SARS‐CoV‐2 (Adv. Healthcare Mater. 26/2023)
Authors: Youseong Kim, In Ho Park, Jiwoo Shin, Jaibyung Choi, Chansol Jeon, Seonghun Jeon, Jeon‐Soo Shin, Hyungil Jung
Journal: Advanced Healthcare Materials (2023)

Theranostics In article 2300889 by Hyungil Jung and co-workers, a sublingually administered mucosal microneedle-based vaccine induces mucosal immunity against SARS-CoV-2 infection. Mucosal immunity protects a patient's lung and respiratory tract from virus infiltration by SARS-CoV-2 specific IgA and it relieves a risk of SARS-CoV-2 related cytokine release syndrome. This research suggests microneedle vaccines are a potential future mucosal vaccination system to prepare for the next pandemic.
Effects of Individual Amino Acids on the Blood Circulation of Biosynthetic Protein Nanocages: Toward Guidance on Surface Engineering (Adv. Healthcare Mater. 26/2023)
Authors: Ao Liang, Wei Zhou, Hui Zhang, Juan Zhang, Xian‐En Zhang, Ti Fang, Feng Li
Journal: Advanced Healthcare Materials (2023)

Protein Nanocages Protein nanocages are promising platforms for nanomedicine. In article 2300502, Ti Fang, Feng Li, and co-workers systematically evaluate the effects of individual proteinogenic amino acids in the form of homo-oligopeptide tags on the blood half-life of protein nanocages. The revealed effects can be a reference for nanoparticle surface engineering using amino acids.
Table of Contents
Journal: American Journal of Hematology (2023)

VINITI (All-Russian Institute of Science & Technological Information) • Web of Science ® (Thomson ISI).For submission instructions, subscription and all other information visit: www.wileyonlinelibrary.com/ajh.Wiley's Corporate Citizenship initiative seeks to address the environmental, social, economic, and ethical challenges faced in our business and which are important to our diverse stakeholder groups.Since launching the initiative, we have focused on sharing our content with those in need, enhancing community philanthropy, reducing our carbon impact, creating global guidelines and best practices for paper use, establishing a vendor code of ethics, and engaging our colleagues and other stakeholders in our efforts.Follow our progress at www.
The tumor-draining lymph node as a reservoir for systemic immune surveillance
Authors: Ines Delclaux, Katherine S. Ventre, Dennis Jones, Amanda W. Lund
Journal: Trends in cancer (2023)

Early in solid tumor development, antigens are presented in tumor-draining lymph nodes (tdLNs), a process that is necessary to set up immune surveillance. Recent evidence indicates that tdLNs fuel systemic tumor-specific T cell responses which may halt cancer progression and facilitate future responses to immunotherapy. These protective responses, however, are subject to progressive dysfunction exacerbated by lymph node (LN) metastasis. We discuss emerging preclinical and clinical literature indicating that the tdLN is a crucial reservoir for systemic immunity that can potentiate immune surveillance. We also discuss the impact of LN metastasis and argue that a better understanding of the relationship between LN metastasis and systemic immunity will be necessary to direct regional disease management in the era of immunotherapy.
Hypoxia-driven protease legumain promotes immunosuppression in glioblastoma
Authors: Lizhi Pang, Songlin Guo, Fatima Khan, Madeline Dunterman, Heba Ali, Yang Liu, Yuyun Huang, Peiwen Chen
Journal: Cell Reports Medicine (2023)

Glioblastoma (GBM) is a hypoxic and "immune-cold" tumor containing rich stromal signaling molecules and cell populations, such as proteases and immunosuppressive tumor-associated macrophages (TAMs). Here, we seek to profile and characterize the potential proteases that may contribute to GBM immunosuppression. Legumain (LGMN) emerges as the key protease that is highly enriched in TAMs and transcriptionally upregulated by hypoxia-inducible factor 1-alpha (HIF1α). Functionally, the increased LGMN promotes TAM immunosuppressive polarization via activating the GSK-3β-STAT3 signaling pathway. Inhibition of macrophage HIF1α and LGMN reduces TAM immunosuppressive polarization, impairs tumor progression, enhances CD8+ T cell-mediated anti-tumor immunity, and synergizes with anti-PD1 therapy in GBM mouse models. Thus, LGMN is a key molecular switch connecting two GBM hallmarks of hypoxia and immunosuppression, providing an actionable therapeutic intervention for this deadly disease.
High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma
Authors: Nadia Arang, Simone Lubrano, Michele Ceribelli, Damiano C. Rigiracciolo, Robert Saddawi-Konefka, Farhoud Faraji, Sydney I. Ramirez, Daehwan Kim, Frances A. Tosto, Erica Stevenson, Yuan Zhou, Zhiyong Wang, Julius Bogomolovas, Alfredo A. Molinolo, Danielle L. Swaney, Nevan J. Krogan, Jing Yang, Silvia Coma, Jonathan A. Pachter, Andrew E. Aplin, Dario R. Alessi, Craig J. Thomas, J. Silvio Gutkind
Journal: Cell Reports Medicine (2023)

Uveal melanoma (UM) is the most prevalent cancer of the eye in adults, driven by activating mutation of GNAQ/GNA11; however, there are limited therapies against UM and metastatic UM (mUM). Here, we perform a high-throughput chemogenetic drug screen in GNAQ-mutant UM contrasted with BRAF-mutant cutaneous melanoma, defining the druggable landscape of these distinct melanoma subtypes. Across all compounds, darovasertib demonstrates the highest preferential activity against UM. Our investigation reveals that darovasertib potently inhibits PKC as well as PKN/PRK, an AGC kinase family that is part of the "dark kinome." We find that downstream of the Gαq-RhoA signaling axis, PKN converges with ROCK to control FAK, a mediator of non-canonical Gαq-driven signaling. Strikingly, darovasertib synergizes with FAK inhibitors to halt UM growth and promote cytotoxic cell death in vitro and in preclinical metastatic mouse models, thus exposing a signaling vulnerability that can be exploited as a multimodal precision therapy against mUM.
Can extracellular vesicles be considered as a potential frontier in the treatment of intervertebral disc disease?
Authors: Shengxu Zhu, Junlin Wang, Moran Suo, Huagui Huang, Xin Liu, Jinzuo Wang, Zhonghai Li
Journal: Ageing Research Reviews (2023)

As a global public health problem, low back pain (LBP) caused by intervertebral disc degeneration (IDD) seriously affects patients' quality of life. In addition, the prevalence of IDD tends to be younger, which brings a huge burden to individuals and society economically. Current treatments do not delay or reverse the progression of IDD. The emergence of biologic therapies has brought new hope for the treatment of IDD. Among them, extracellular vesicles (EVs), as nanoscale bioactive substances that mediate cellular communication, have now produced many surprising results in the research of the treatment of IDD. This article reviews the mechanisms and roles of EVs in delaying IDD and describes the prospects and challenges of EVs.
Functional interrogation of twenty type 2 diabetes-associated genes using isogenic human embryonic stem cell-derived β-like cells
Authors: Dongxiang Xue, Narisu Narisu, D. Leland Taylor, Meili Zhang, Caleb Grenko, Henry J. Taylor, Tingfen Yan, Xuming Tang, Neelam Sinha, Jiajun Zhu, J. Jeya Vandana, Angie Chi Nok Chong, Angela Lee, Erin C. Mansell, Amy J. Swift, Michael R. Erdos, Aaron Zhong, Lori L. Bonnycastle, Ting Zhou, Shuibing Chen, Francis S. Collins
Journal: Cell Metabolism (2023)

Genetic studies have identified numerous loci associated with type 2 diabetes (T2D), but the functional roles of many loci remain unexplored. Here, we engineered isogenic knockout human embryonic stem cell lines for 20 genes associated with T2D risk. We examined the impacts of each knockout on β cell differentiation, functions, and survival. We generated gene expression and chromatin accessibility profiles on β cells derived from each knockout line. Analyses of T2D-association signals overlapping HNF4A-dependent ATAC peaks identified a likely causal variant at the FAIM2 T2D-association signal. Additionally, the integrative association analyses identified four genes (CP, RNASE1, PCSK1N, and GSTA2) associated with insulin production, and two genes (TAGLN3 and DHRS2) associated with β cell sensitivity to lipotoxicity. Finally, we leveraged deep ATAC-seq read coverage to assess allele-specific imbalance at variants heterozygous in the parental line and identified a single likely functional variant at each of 23 T2D-association signals.
Analysis of blood and nasal epithelial transcriptomes to identify mechanisms associated with control of SARS-CoV-2 viral load in the upper respiratory tract
Authors: Mahdi Moradi Marjaneh, Joseph D. Challenger, Antonio Salas, Alberto Gómez-Carballa, Abilash Sivananthan, Irene Rivero-Calle, Gema Barbeito-Castiñeiras, Cher Y. Foo, Yue Wu, Felicity Liew, Heather R. Jackson, Dominic Habgood-Coote, Giselle D’Souza, Samuel J. Nichols, Victoria J. Wright, Michael Levin, Myrsini Kaforou, Ryan S. Thwaites, Lucy C. Okell, Federico Martinón-Torres, Aubrey J. Cunnington
Journal: Journal of Infection (2023)

The amount of SARS-CoV-2 detected in the upper respiratory tract (URT viral load) is a key driver of transmission of infection. Current evidence suggests that mechanisms constraining URT viral load are different from those controlling lower respiratory tract viral load and disease severity. Understanding such mechanisms may help to develop treatments and vaccine strategies to reduce transmission. Combining mathematical modelling of URT viral load dynamics with transcriptome analyses we aimed to identify mechanisms controlling URT viral load. COVID-19 patients were recruited in Spain during the first wave of the pandemic. RNA sequencing of peripheral blood and targeted NanoString nCounter transcriptome analysis of nasal epithelium were performed and gene expression analysed in relation to paired URT viral load samples collected within 15 days of symptom onset. Proportions of major immune cells in blood were estimated from transcriptional data using computational differential estimation. Weighted correlation network analysis (adjusted for cell proportions) and fixed transcriptional repertoire analysis were used to identify associations with URT viral load, quantified as standard deviations (z-scores) from an expected trajectory over time. Eighty-two subjects (50% female, median age 54 years (range 3–73)) with COVID-19 were recruited. Paired URT viral load samples were available for 16 blood transcriptome samples, and 17 respiratory epithelial transcriptome samples. Natural Killer (NK) cells were the only blood cell type significantly correlated with URT viral load z-scores (r = −0.62, P = 0.010). Twenty-four blood gene expression modules were significantly correlated with URT viral load z-score, the most significant being a module of genes connected around IFNA14 (Interferon Alpha-14) expression (r = −0.60, P = 1e-10). In fixed repertoire analysis, prostanoid-related gene expression was significantly associated with higher viral load. In nasal epithelium, only GNLY (granulysin) gene expression showed significant negative correlation with viral load. Correlations between the transcriptional host response and inter-individual variations in SARS-CoV-2 URT viral load, revealed many molecular mechanisms plausibly favouring or constraining viral replication. Existing evidence corroborates many of these mechanisms, including likely roles for NK cells, granulysin, prostanoids and interferon alpha-14. Inhibition of prostanoid production and administration of interferon alpha-14 may be attractive transmission-blocking interventions.
Self-sufficient nanoparticles with dual-enzyme activity trigger radical storms and activate cascade-amplified antitumor immunologic responses
Authors: Liping Bai, Jin Yang, Siting Yu, Zhongzheng Xiang, Yuanyuan Zeng, Meiling Shen, Xiaorong Kou, Qinjie Wu, Changyang Gong
Journal: Acta Pharmaceutica Sinica B (2023)

Radiotherapy (RT) can potentially induce systemic immune responses by initiating immunogenic cell death (ICD) of tumor cells. However, RT-induced antitumor immunologic responses are sporadic and insufficient against cancer metastases. Herein, we construct multifunctional self-sufficient nanoparticles (MARS) with dual-enzyme activity (GOx and peroxidase-like) to trigger radical storms and activate the cascade-amplified systemic immune responses to suppress both local tumors and metastatic relapse. In addition to limiting the Warburg effect to actualize starvation therapy, MARS catalyzes glucose to produce hydrogen peroxide (H
Association of Redlining and Natural Environment with Depressive Symptoms in Women in the Sister Study
Authors: Wei-Lun Tsai, Maliha S. Nash, Daniel J. Rosenbaum, Steven E. Prince, Aimee A. D’Aloisio, Megan H. Mehaffey, Dale P. Sandler, Timothy J. Buckley, Anne C. Neale
Journal: Environmental Health Perspectives (2023)

Improving mental health is recognized as an important factor for achieving global development goals. Despite strong evidence that neighborhood greenery promotes better mental health, there are environmental justice concerns over the distribution of neighborhood greenery. Underlying these concerns are present-day consequences of historical discriminatory financial investment practices, such as redlining which was established by the U.S. Federal Home Owners' Loan Corporation (HOLC) in the 1930s. The impacts of redlining on environmental and health disparities have been researched extensively. However, the influences of redlining on the associations between neighborhood environment and health outcomes have not been fully assessed.
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
Authors: Anna C Pavlick, Charlotte E Ariyan, Elizabeth I Buchbinder, Diwakar Davar, Geoffrey T Gibney, Omid Hamid, Tina J Hieken, Benjamin Izar, Douglas B Johnson, Rajan P Kulkarni, Jason J Luke, Tara C Mitchell, Meghan J Mooradian, Krista M Rubin, April KS Salama, Keisuke Shirai, Janis M Taube, Hussein A Tawbi, J Keith Tolley, Caressa Valdueza, Sarah A Weiss, Michael K Wong, Ryan J Sullivan
Journal: Journal for ImmunoTherapy of Cancer (2023)

Since the first approval for immune checkpoint inhibitors (ICIs) for the treatment of cutaneous melanoma more than a decade ago, immunotherapy has completely transformed the treatment landscape of this chemotherapy-resistant disease. Combination regimens including ICIs directed against programmed cell death protein 1 (PD-1) with anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) agents or, more recently, anti-lymphocyte-activation gene 3 (LAG-3) agents, have gained regulatory approvals for the treatment of metastatic cutaneous melanoma, with long-term follow-up data suggesting the possibility of cure for some patients with advanced disease. In the resectable setting, adjuvant ICIs prolong recurrence-free survival, and neoadjuvant strategies are an active area of investigation. Other immunotherapy strategies, such as oncolytic virotherapy for injectable cutaneous melanoma and bispecific T-cell engager therapy for HLA-A*02:01 genotype-positive uveal melanoma, are also available to patients. Despite the remarkable efficacy of these regimens for many patients with cutaneous melanoma, traditional immunotherapy biomarkers (ie, programmed death-ligand 1 expression, tumor mutational burden, T-cell infiltrate and/or microsatellite stability) have failed to reliably predict response. Furthermore, ICIs are associated with unique toxicity profiles, particularly for the highly active combination of anti-PD-1 plus anti-CTLA-4 agents. The Society for Immunotherapy of Cancer (SITC) convened a panel of experts to develop this clinical practice guideline on immunotherapy for the treatment of melanoma, including rare subtypes of the disease (eg, uveal, mucosal), with the goal of improving patient care by providing guidance to the oncology community. Drawing from published data and clinical experience, the Expert Panel developed evidence- and consensus-based recommendations for healthcare professionals using immunotherapy to treat melanoma, with topics including therapy selection in the advanced and perioperative settings, intratumoral immunotherapy, when to use immunotherapy for patients with
Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer
Authors: Mehmet Akce, Batoul Farran, Jeffrey M Switchenko, Manali Rupji, Sandra Kang, Lana Khalil, Amanda Ruggieri-Joyce, Brian Olson, Walid L Shaib, Christina Wu, Olatunji B Alese, Maria Diab, Gregory B Lesinski, Bassel F El-Rayes
Journal: Journal for ImmunoTherapy of Cancer (2023)

Background Preclinical studies showed metformin reduces exhaustion of tumor-infiltrating lymphocytes and potentiates programmed cell death protein-1 (PD-1) blockade. We hypothesized that metformin with nivolumab would elicit potent antitumor and immune modulatory activity in metastatic microsatellite stable (MSS) colorectal cancer (CRC). We evaluated this hypothesis in a phase II study. Methods Nivolumab (480 mg) was administered intravenously every 4 weeks while metformin (1000 mg) was given orally, two times per day following a 14-day metformin only lead-in phase. Patients ≥18 years of age, with previously treated, stage IV MSS CRC, and Eastern Cooperative Oncology Group 0–1, having received no prior anti-PD-1 agent were eligible. The primary endpoint was overall response rate with secondary endpoints of overall survival (OS) and progression-free survival (PFS). Correlative studies using paired pretreatment/on-treatment biopsies and peripheral blood evaluated a series of immune biomarkers in the tumor microenvironment and systemic circulation using ChipCytometry and flow cytometry. Results A total of 24 patients were enrolled, 6 patients were replaced per protocol, 18 patients had evaluable disease. Of the 18 evaluable patients, 11/18 (61%) were women and the median age was 58 (IQR 50–67). Two patients had stable disease, but no patients had objective response, hence the study was stopped for futility. Median OS and PFS was 5.2 months (95% CI (3.2 to 11.7)) and 2.3 months (95% CI (1.7 to 2.3)). Most common grade 3/4 toxicities: Anemia (n=2), diarrhea (n=2), and fever (n=2). Metformin alone failed to increase the infiltration of T-cell subsets in the tumor, but combined metformin and nivolumab increased percentages of tumor-infiltrating leukocytes (p=0.031). Dual treatment also increased Tim3+ levels in patient tissues and decreased naïve CD8+T cells (p=0.0475). Conclusions Nivolumab and metformin were well tolerated in patients with MSS CRC but had no evidence of efficacy. Correlative studies did not reveal an appreciable degree of immune modulation from metformin alone, but showed trends in tumorous T-cell infiltration as a result of dual metformin and PD-1 blockade despite progression in a majority of patients.